Combo product QSR
This article was originally published in The Gray Sheet
Executive Summary
Combination product compliance with device quality system regulations and drug current good manufacturing practices "can generally be achieved" by following either set of regs when the components are produced together, since "under a more general requirement in one set of regulations, it will be possible to develop and implement a practice that complies with a more specific requirement in the other set," FDA explains in a 1Sept. 29 draft guidance. On Sept. 27, the agency released a new list of jurisdictional determinations: combo products under CDRH include coronary stents with biologicals, orthopedic prostheses with growth factors, dialysate with drug components, and vascular grafts with antibiotics. The designations are based on "primary mode of action" (2"The Gray Sheet" May 10, 2004, p. 12)...
You may also be interested in...
Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.